Characterization of serum neutralization response to the human immunodeficiency virus (HIV).
Characterization of serum neutralization response to the human immunodeficiency virus (HIV).
复制标题
DOI：
--
复制
发表时间：
1987
影响因子：
1.5
通讯作者：
J. Groopman;P. Benz;R. Ferriani;K. Mayer;J. Allan;L. Weymouth
中科院分区：
文献类型：
--
作者：
J. Groopman;P. Benz;R. Ferriani;K. Mayer;J. Allan;L. Weymouth
为了确定人类免疫缺陷病毒（HIV）中和抗体的临床意义，我们测量了HIV感染后不同临床结局患者的血清中和水平。血清中和滴度从小于1:5到1:100不等。HIV感染后的中和反应出现缓慢，在血清转化后7个月，中和滴度仍然很低，在1:5或以下。78例艾滋病、艾滋病相关复发物或无症状的HIV血清阳性受试者，其滴度与临床状态没有明显差异。然而，与机会性感染的艾滋病患者相比，卡波西肉瘤患者中和效价为1:20或更高的比例（11/12）更高。用Western blot分析血清样品对特定病毒蛋白的反应性。临床状态不能通过特定的血清学特征来预测。然而，与HIV主包膜糖蛋白gp120反应的血清往往具有更高的中和效价，这表明gp120可能是人类抗HIV中和抗体的靶点。
To determine the clinical significance of human neutralizing antibodies to the human immunodeficiency virus (HIV), we measured serum neutralization in patients with different clinical outcomes following HIV infection. Serum neutralization titers ranged from less than 1:5 to 1:100. The neutralization response after HIV infection appeared slow, with neutralization titers remaining low, at or below 1:5, at 7 months following seroconversion. Comparison of 78 HIV seropositive subjects with AIDS, AIDS-related complex, or no symptoms failed to reveal any significant differences in titer which correlated with clinical status. However, a greater proportion of AIDS patients with Kaposi's sarcoma (11/12) had neutralization titers of 1:20 or greater than did AIDS patients with opportunistic infections (2/11). Serum samples were analyzed by Western blot for their reactivity to specific viral proteins. Clinical status could not be predicted by a particular serological profile. However, sera which reacted with the HIV major envelope glycoprotein gp120 tended to have higher neutralization titers, suggesting that gp120 may be a target of anti-HIV neutralizing antibody in man.